Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666430 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
A Phase 3 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT02666430 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 127 participants.
The verdict
NCT02666430, a Phase 3 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
Interventions
- DRUG Mylan's insulin glargine
- DRUG Lantus®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02666430
The ClinicalTrials.gov registry entry for NCT02666430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mylan's insulin glargine is the first listed.
NCT02666430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02666430 about?
NCT02666430 is a clinical study titled "Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients". The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
What is the current status of trial NCT02666430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2015-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02666430?
The interventions under investigation include: Mylan's insulin glargine (DRUG), Lantus® (DRUG).
Who is sponsoring clinical trial NCT02666430?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.